Loading financial data...

Black Diamond Therapeutics, Inc. (BDTX) Financial Statements | Global Financial Data

Black Diamond Therapeutics, Inc.

BDTXSEC EDGAR

Biological Products, (No Diagnostic Substances)CIK: 1701541

Concept	FY2024	FY2023	FY2022	FY2021	FY2020
Revenue from Contract with Customer, Excluding Assessed Tax	—	—	—	—	$0.00
Research and Development Expense	$59.4M	$64.4M	$96.8M	$48.2M	$21.8M
Operating Expenses	$86.5M	$92.8M	$126.9M	$69.6M	$3.8M
Operating Income (Loss)	-$86.5M	-$92.8M	-$126.9M	-$69.6M	-$3.8M
Interest Expense	—	—	—	$1.0K	$0.00
Nonoperating Income (Expense)	$4.0M	$3.9M	$1.3M	$2.3M	-$5.9M
Income Tax Expense (Benefit)	$0.00	$0.00	$0.00	$0.00	$0.00
Net Income (Loss) Attributable to Parent

Concept	FY2024	FY2023	FY2022	FY2021	FY2020
Assets	$158.6M	$156.3M	$247.7M	$329.7M	$158.3M
Assets, Current	$134.0M	$127.7M	$215.7M	$319.6M	$155.7M
Cash and Cash Equivalents, at Carrying Value	$56.2M	$34.3M	$65.8M	$34.6M	$154.7M
Liabilities	$41.8M	$40.6M	$51.8M	$21.9M	$4.9M
Liabilities, Current	$19.6M	$15.3M	$23.6M	$14.2M	$4.9M
Accounts Payable, Current	$2.3M	$1.9M	$4.1M	$2.5M	$2.0M
Stockholders' Equity Attributable to Parent	$115.7M	$195.9M	$307.8M	-$47.2M

Concept	FY2024	FY2023	FY2022	FY2021	FY2020
Net Cash Provided by (Used in) Operating Activities	-$66.7M	-$85.1M	-$100.1M	-$52.1M	-$24.7M
Net Cash Provided by (Used in) Investing Activities	$16.3M	$53.4M	$130.6M	-$281.7M	-$21.0K
Net Cash Provided by (Used in) Financing Activities	$71.9M	$177.0K	$729.0K	$214.9M	$127.8M
Payments to Acquire Property, Plant, and Equipment	$33.0K	$192.0K	$2.7M	$142.0K	$21.0K

Access SEC EDGAR data via REST API. Free tier available.

from sec_edgar import SecEdgar

api = SecEdgar("YOUR_KEY")
api.revenue("AAPL", limit=5)